IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3418
Positioning
Market Dominance
Manufacturing
Medical Equipment
$219M
Lishan Aklog
Lucid Diagnostics Inc. focuses on patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux or simply reflux. The company was incorporated in 2018 and is based in New York, New York.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$LUCD Lucid Diagnostics Inc. | 41 | 21 | 33 | 46 | - | - | -209.5% | -101.7% | 100.0% | -1113.9% | -1386.4% | 24.1% | 0.0% | 106.0x | $219M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Lucid Diagnostics Inc. (LUCD) receives a "Reduce" rating with a composite score of 41.0/100. It ranks #3418 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Lishan Aklog
Chief Executive Officer
21
30
51
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for LUCD
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for LUCD.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 21 | 2 | +19ALPHA |
| MOMENTUM | 46 | 30 | +16ALPHA |
| VALUATION | 33 | 13 | +20ALPHA |
| INVESTMENT | 30 | 34 | -4NEUTRAL |
| STABILITY | 51 | 35 | +16ALPHA |
| SHORT INT | 47 | 43 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -209.5% (sector -2.5%)
GM 100% vs sector 43%, OM -1114% vs sector 1%
Capital turnover N/A, R&D intensity 123.5%
Rev growth 24%, 5yr history
Interest coverage -5879.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Lucid Diagnostics Inc. receives a Reduce rating from our analysis, with a composite score of 41.0/100 and 2 out of 5 stars, ranking #3418 out of 7,333 stocks. LUCD's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
Lucid Diagnostics Inc. registers a weak quality score of just 21/100, indicating significant profitability challenges. The company reports a return on equity of -209.5% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -1386.4% (sector avg: -0.2%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 33/100, LUCD appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 6.90x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Lucid Diagnostics Inc.'s investment score of 30/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 24.1% vs. a sector average of 5.9% and a return on assets of -101.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
LUCD is currently showing below-average momentum at 46/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 24.1% year-over-year, while a beta of 0.78 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 51/100, LUCD exhibits average financial resilience. Key stability metrics include a beta of 0.78 and a debt-to-equity ratio of 106.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 47/100 for LUCD suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 106.00x), micro-cap liquidity risk. With a $219M market cap (micro-cap), Lucid Diagnostics Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Lucid Diagnostics Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3418 of 7,333 overall (53rd percentile). Key comparisons include ROE of -209.5% trailing the -2.5% sector median and operating margins of -1113.9% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While LUCD currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (21) would have the largest impact on the composite score.
ROE 8346% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 86452% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Lucid Diagnostics Inc. (LUCD) as a Reduce with a composite score of 41.0/100 at a current price of $1.46. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in stability (51th percentile) and momentum (46th percentile), which together account for the majority of the composite score. Offsetting weakness in quality (21th percentile) and investment (30th percentile) tempers our overall conviction. We assign a No Moat rating (36/100), High uncertainty, and Poor capital allocation.
Key items to watch: balance sheet deleveraging progress; sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Lucid Diagnostics Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.0/100 places it at rank #3418 in our full 7,333-stock universe. At $219M in market capitalization, Lucid Diagnostics Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 24%, though momentum at the 46th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -1114% (-1115.2pp vs sector) and net margins of -1386.4%, yielding a gross-to-net conversion rate of -1386%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $1.46, Lucid Diagnostics Inc. is trading at a premium to fundamental value. Our value factor score of 33/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at P/B of 6.9x, P/S of 40.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 24% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
The Reduce rating (composite 41.0/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Elevated leverage (106% D/E) amplifies downside risk and limits management's financial flexibility in adverse scenarios.
Thin net margins of -1386.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to Lucid Diagnostics Inc.. Key risk factors include significant leverage (106% debt-to-equity), current negative profitability (net margin -1386.4%), weak quality scores (21th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: significant leverage (106% debt-to-equity); current negative profitability (net margin -1386.4%); weak quality scores (21th percentile); the combination of leverage (106% D/E) and thin margins (-1386.4% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 51th percentile and quality factor at the 21th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Lucid Diagnostics Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-209.5%), negative profitability, weak asset returns (ROA -101.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Lucid Diagnostics Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Lucid Diagnostics Inc. receives a Reduce rating with a composite score of 41.0/100 (rank #3418 of 7,333). Our quantitative framework assigns a No Moat (36/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 36/100.
Our analysis does not support a constructive view on Lucid Diagnostics Inc. at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign Lucid Diagnostics Inc. a meaningful economic moat, scoring 36/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 10.4/20.
The strongest moat sources are margin superiority (10.4/20) and growth durability (10/20). GM 100% vs sector 43%, OM -1114% vs sector 1%. Rev growth 24%, 5yr history. These pillars form the core of Lucid Diagnostics Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.5/20) and financial resilience (5.8/20). ROE proxy -209.5% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Lucid Diagnostics Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 24% expanding the revenue base. The margin cascade from 100% gross to -1114% operating to -1386.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 21th percentile.
The margin profile shows gross margins of 100%, operating margins of -1114%, net margins of -1386.4%. Return metrics include ROE of -209.5% and ROA of -101.7%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -209.5% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 106%, revenue growth of 24%. The sector median D/E is 0%, putting Lucid Diagnostics Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Below-average quality (21th percentile) raises durability concerns about the fundamental profile and increases the risk of negative earnings surprises.
Above 50MA
37.18%
Net New Highs
+51081
Key Insights Lucid Diagnostics' significant individual investors ownership suggests that the key decisions are...
Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually.
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out to be negative for several others engaged in COVID-19 vaccine and treatment research. Pfizer announced Friday its oral COVID-19 pill Paxlovid reduced the risk of COVID-19-related hospitalization or death by 89%. Merck & Co., Inc. (MRK: NYSE), which also has a competing medication in the pipeline, shed close to 10% on Friday. Stocks also reacted to the earnings, which came in thick and fast during the week. Five stocks belonging to the biotech and diagnostics spaces, debuted on Wall Street during the week. Here are the key upcoming catalysts that biotech investors are on in the unfolding week: Health Care Conferences: American College of Rheumatology, or ACR, Convergence 2021: Nov. 3-9 (virtual) BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology: Nov. 8 (virtual event) Credit Suisse 30th Annual Virtual Healthcare Conference: Nov. 8-11 (virtual conference) 14th Clinical Trial On Alzheimer's Disease, or CTAD, 2021: Nov. 9-12 (in Boston) 6th Respiratory Syncytial Virus Network, or RESVINET, Conference: Nov. 10-12 (virtual meeting) Society For Immunotherapy of Cancer: Nov. 10-14 (hybrid event, to be held in Washington, D.C. and to be available virtually) Connective Tissue Oncology Society, or CTOS, 2021 Annual Meeting: Nov. 10-13 (virtual meeting) American Academy of Ophthalmology, or AAO, 2021 Meeting: Nov. 12-13 (in New Orleans) American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2021: Nov. 12-15 (virtual meeting) Clinical Readouts/Presentations Liver Meeting Presentations Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA): Phase 1b data for EDP-514 in viremic, chronic hepatitis B infected patients Vir Biotechnology, Inc. (NASDAQ: VIR): Preliminary results from a Phase 1 study evaluating a single dose of VIR-3434, a novel neutralizing, vaccinal monoclonal antibody, for hepatitis B infection (Friday, at 8 a.m.) Vaccitech plc (NASDAQ: VACC): Interim results of HBV001, a Phase 1 study evaluating therapeutic vaccination with ChAdOx1-HBV in healthy volunteers and patients with chronic hepatitis B infection; Phase 1b/2a study of heterologous ChAdOx1/MVA therapeutic vaccination combined with Bristol-Myers Squibb Company's (NYSE: BMY) low-dose Opdivo in virally-suppressed patients with CHB under nucleos(t)ide analogues Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA): results of a subpopulation pharmacokinetic and safety analysis from the Phase 1 trial of RG6346, which Dicerna is developing in collaboration with Roche Holding AG (OTC: RHHBY) for the treatment of chronic hepatitis B virus infection; interim Phase 1 data from Belcesiran in Alpha 1-antitrypsin deficiency-associated liver disease Lipocine Inc. (NASDAQ: LPCN): safety And tolerability Of LPCN 1144 treatment In biopsy confirmed NASH subjects from the Phase 2 LiFT study Arbutus Biopharma Corporation (NASDAQ: ABUS): data on the effects of its ...
PAVmed Inc. announced a 1-for-30 reverse stock split effective January 2, 2026, to comply with Nasdaq's $1.00 minimum bid price requirement. The split was approved by stockholders on December 5, 2025, and authorized shares will be reduced from 250 million to 25 million. The company's stock will continue trading under symbol PAVM on Nasdaq Capital Market.
Lucid Diagnostics will host a business update conference call on November 12, 2025, at 8:30 AM ET, where CEO Lishan Aklog will discuss company operations and growth strategy, and CFO Dennis McGrath will review Q3 2025 financial results.